Vertex Pharmaceuticals Incorporated, headquartered in Boston, Massachusetts, is a prominent American biopharmaceutical company founded in 1989. Known for pioneering rational drug design, Vertex developed groundbreaking cystic fibrosis treatments like Kalydeco, Orkambi, and Trikafta, which target the disease’s root causes. The company’s expanding pipeline includes therapies for severe conditions such as Type 1 Diabetes, sickle cell disease, and beta-thalassemia. Vertex also advances gene-editing therapies through critical collaborations, including those with CRISPR Therapeutics.